Zota Health Care Limited announced the transcript of the Q4FY25/FY25 earnings conference call held on May 30, 2025.
The company's mission is to make healthcare affordable for all, focusing on manufacturing, marketing, and exporting pharmaceutical, ayurvedic, nutraceutical, and OTC products.
Zota operates through four key verticals:
Retail pharmacy chain - Davaindia
Domestic marketing business
Export business
Everyday Herbal Group
Davaindia has grown to 1,637 active stores as of May 16, 2025, offering generic medicines at 30% to 90% lower prices than branded counterparts.
901 COCO stores are operational as of May 16, with an online B2C platform for doorstep delivery.
736 FOFO stores are also in operation.
Domestic Marketing Business distributes branded medicines, OTC, and pharmaceutical products through 1,050 distributors nationwide, with a portfolio of around 4,000 products.
Export business has a presence in over 30 countries, with 325 product approvals out of 586 dossiers submitted.
In 2024, Zota acquired a 56% stake in Everyday Herbal Group to strengthen its OTC and cosmetic product portfolio.
Consolidated revenue from operations grew by 62% year-on-year, reaching ₹292.98 crore from ₹180 crore in FY24. Davaindia contributed ₹186 crore, growing 80% year-on-year.
Domestic sales stood at ₹63 crore, growing 11% year-on-year, while export business grew at 59%, reaching ₹32 crore.
Everyday Herbal Group contributed ₹11 crore to the revenue.
Gross profit increased by 86% year-on-year, reaching ₹155 crore compared to ₹84 crore in FY24.
Zota expanded its Davaindia network to 1,582 stores as of March 31, 2025, including 852 COCO stores and 730 FOFO stores, adding 702 new stores during FY25.
Customer footfall increased from 51.8 lakh to 97.7 lakh, and GMV rose sharply to ₹245 crore from ₹137 crore.
The company plans to add more than 1.6 COCO stores per day in FY26, with potential for faster expansion.
The company closed 18-19 COCO stores in the last quarter due to relocation and inventory-related losses.
EBITDA may remain flat for the current financial year due to aggressive expansion, with plans to open approximately 800 to 900 more COCO stores.
The company plans to expand into insulin and other diabetes-related therapies, actively tracking off-patent opportunities.
The company is willing to explore better efficiencies in supply chain.
Himanshu Zota (Founder and Whole Time Director) mentioned that for 36 month old stores the average GMV per store is around ₹6.4 lakhs per month, and store-level EBITDA is approximately ₹1.5 lakhs per month per store.